Animal models of respiratory syncytial virus infection

被引:89
作者
Byrd, LG [1 ]
Prince, GA [1 ]
机构
[1] Vir Syst, Rockville, MD 20850 USA
关键词
D O I
10.1086/516152
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past two decades, animal models of respiratory syncytial virus (RSV) infection have been developed using primates, cotton rats, mice, calves, guinea pigs, ferrets, and hamsters. Use of these models has shed light on the mechanisms of vaccine-enhanced disease seen in clinical trials of a formalin-inactivated RSV vaccine and has provided a means for testing efficacy and safety of candidate prophylactic and therapeutic strategies. The development of multiple animal models has coincided with the realization that RSV disease in humans is a multifaceted disease whose clinical manifestations and sequelae depend upon age, genetic makeup, immunologic status, and concurrent disease within subpopulations. There is no single human subpopulation in whom all forms of RSV disease manifest, nor is there a single animal model that duplicates all forms of RSV disease. The choice of an experimental model will be governed by the specific manifestation of disease to be studied.
引用
收藏
页码:1363 / 1368
页数:6
相关论文
共 65 条
[11]   A COMPARISON IN CHIMPANZEES OF THE IMMUNOGENICITY AND EFFICACY OF LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS (RSV) TEMPERATURE-SENSITIVE MUTANT VACCINES AND VACCINIA VIRUS RECOMBINANTS THAT EXPRESS THE SURFACE GLYCOPROTEINS OF RSV [J].
CROWE, JE ;
COLLINS, PL ;
LONDON, WT ;
CHANOCK, RM ;
MURPHY, BR .
VACCINE, 1993, 11 (14) :1395-1404
[12]   Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates [J].
Crowe, JE ;
Bui, PT ;
Firestone, CY ;
Connors, M ;
Elkins, WR ;
Chanock, RM ;
Murphy, BR .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (04) :829-839
[13]   A FURTHER ATTENUATED DERIVATIVE OF A COLD-PASSAGED TEMPERATURE-SENSITIVE MUTANT OF HUMAN RESPIRATORY SYNCYTIAL VIRUS RETAINS IMMUNOGENICITY AND PROTECTIVE EFFICACY AGAINST WILD-TYPE CHALLENGE IN SERONEGATIVE CHIMPANZEES [J].
CROWE, JE ;
BUI, PT ;
DAVIS, AR ;
CHANOCK, RM ;
MURPHY, BR .
VACCINE, 1994, 12 (09) :783-790
[14]  
Dreizin R S, 1971, Vopr Virusol, V16, P670
[15]   A PROTOTYPE RECOMBINANT VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA VIRUS TYPE-3 [J].
DU, RP ;
JACKSON, GED ;
WYDE, PR ;
YAN, WY ;
WANG, QJ ;
GISONNI, L ;
SANHUEZA, SE ;
KLEIN, MH ;
EWASYSHYN, ME .
BIO-TECHNOLOGY, 1994, 12 (08) :813-818
[16]  
GERSHWIN L, 1996, RSV 40 YEARS ANN S K
[17]   RISK OF PRIMARY INFECTION AND REINFECTION WITH RESPIRATORY SYNCYTIAL VIRUS [J].
GLEZEN, WP ;
TABER, LH ;
FRANK, AL ;
KASEL, JA .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1986, 140 (06) :543-546
[18]   Immunological determinants of disease caused by respiratory syncytial virus [J].
Graham, BS .
TRENDS IN MICROBIOLOGY, 1996, 4 (07) :290-294
[19]   PRIMARY RESPIRATORY SYNCYTIAL VIRUS-INFECTION IN MICE [J].
GRAHAM, BS ;
PERKINS, MD ;
WRIGHT, PF ;
KARZON, DT .
JOURNAL OF MEDICAL VIROLOGY, 1988, 26 (02) :153-162
[20]  
GRAHAM BS, 1993, J IMMUNOL, V151, P2032